Literature DB >> 2208574

Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.

M Limonta1, A Biondi, G Giudici, G Specchia, C Catapano, G Masera, T Barbui, M D'Incalci.   

Abstract

4-Demethoxydaunorubicin (4-DMDR) and its major metabolite 4-demethoxy-13-hydroxydaunorubicin (4-DMDRol) were investigated for their cytotoxicity and mode of action against human leukemic cells. The drug and its metabolite appeared to be equally potent as both inhibitors of cell proliferation and inducers of DNA double-strand breaks in the OCI AML-3 cell line and cells derived directly from patients with acute myeloid leukemia (AML). This suggests that 4-DMDRol plays an important role in the antileukemic activity of 4-DMDR.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2208574     DOI： 10.1007/bf02897289

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  10 in total

1.  Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.

Authors:  L Zanette; M Zucchetti; A Freshi; D Erranti; U Tirelli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients.

Authors:  R M Lowenthal; C N Chesterman; J D Griffiths; A Manoharan; M G Harris; R P Herrmann; K F Rooney; M C Rozenberg; H H Salem; M M Wolf
Journal:  Cancer Treat Rep       Date:  1987-12

3.  Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.

Authors:  E Madon; G Grazia; B De Bernardi; A Comelli; M Carli; L Sainati; G Paolucci; R Canino; R Colella; S Bagnulo
Journal:  Cancer Treat Rep       Date:  1987-09

4.  Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.

Authors:  J L Harousseau; P Hurteloup; J Reiffers; F Rigal-Huguet; M Hayat; P Dufour; P Y Le Prise; M Monconduit; J Jaubert; Y Carcassonne
Journal:  Cancer Treat Rep       Date:  1987-10

5.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

Review 6.  Clonogenic cells in acute myeloblastic leukemia.

Authors:  J D Griffin; B Löwenberg
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

7.  Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.

Authors:  F Arcamone; L Bernardi; P Giardino; B Patelli; A Marco; A M Casazza; G Pratesi; P Reggiani
Journal:  Cancer Treat Rep       Date:  1976-07

8.  Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo).

Authors:  G Belvedere; A Suarato; C Geroni; F C Giuliani; M D'Incalci
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

9.  Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.

Authors:  G Capranico; C Soranzo; F Zunino
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin.

Authors:  P A Speth; F A van de Loo; P C Linssen; H M Wessels; C Haanen
Journal:  Clin Pharmacol Ther       Date:  1986-12       Impact factor: 6.875
  10 in total
  4 in total

1.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

3.  Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

Authors:  T Yamaoka; M Hanada; S Ichii; S Morisada; T Noguchi; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1999-06

4.  Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

Authors:  T Yamaoka; M Hanada; S Ichii; S Morisada; T Noguchi; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1998-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.